Therapeutic potential of Janus kinase 3 (JAK3) inhibitors

Current Pharmaceutical Design

Volumn 10, Issue 15, 2004, Pages 1767-1784

  Cetkovic Cvrlje, M ^a   Tibbles, H E ^a  

^a Parker Hughes Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMO 4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3' BROMO 4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (3',5' DIBROMO 4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (3,5 DIBROMO 4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; AZATHIOPRINE; CT 2576; CYCLOSPORIN A; ENZYME INHIBITOR; FUSIDATE SODIUM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JANUS KINASE; JANUS KINASE 3 INHIBITOR; LEFLUNOMIDE; METHOTREXATE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PNU 156804; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; ROQUINIMEX; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; TACROLIMUS; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHMA; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; DRUG POTENTIATION; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LEUKEMIA CELL; MAST CELL; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIDE EFFECT; THROMBOEMBOLISM;

ANIMALS; ENZYME INHIBITORS; HUMANS; JANUS KINASE 3; PROTEIN-TYROSINE KINASES;

EID: 2442464602     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384529     Document Type: Review

References (234)

1. Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zurcher G, Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991; 11: 2057-2065.
2. Harpur AG, Andreas AC, Ziemiecki A, Aston RR, Wilks AF. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 1992; 7: 1347-1353.
3. Takahashi T, Shirasawa T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett 1994; 342: 124-128.
4. Krolewski JJ, Lee R, Eddy R, Shows TB, Dalla-Favera R. Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene 1990; 5: 277-282.
5. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protin tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992; 70: 313-322.
6. Muller M, Briscoe J, Laxton C, Guschin D, Ziemicki A, Silvennoinen O, et al. The protein tyrosine kinase JAK1 complements defects in intrferon-alpha/beta and-gamma signal transduction. Nature 1993; 366: 114-116.
7. Leonard WJ, O'Shea JJ. Jaks and Stats: Biological implications. Annu Rev Immunol 1998; 16: 293-322.
8. Schindler CW. Series introduction. JAK-STAT signaling in human disease. J Clin Invest 2002; 109(9): 1133-7.
9. Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN, et al. Identification o JAK2 as a growth hormone receptor-associatd tyrosine kinase. Cell 1993; 74: 237-44.
10. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74: 227-36.
11. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002; 285(1-2): 1-24.
12. Miyazaki T, Taniguchi T. Coupling of the IL2 receptor complex with non-receptor protien tyrosine kinases. Cancer Surveys 1996; 27: 25-39.
13. Levy DE. The house that Jak/Stat built. Cytokine Growth Factor Rev 1997; 8: 81-90.
14. Ihle JN, Kerr IR. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995; 11: 69-74.
15. Vassilev AO, Lorenz DR, Tibbles HE, Uckun FM. Role of the leukemia-associated transcription factor STAT3 in platelet physiology. Leuk Lymphoma 2002; 43(7): 1461-7.
16. Darnell JEJ, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
17. Kawamura M, McVicar DW, Johnston JA, Blake TB, Chen YQ, Lal BK, et al. Molecular cloning of L-JAK, a Janus family protein kinase expressed i natural killer cels and activated leukocytes. Proc Natl Acad Sci USA 1994; 91: 6374-6378.
18. Gurniak CB, Berg LJ. Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells. Blood 1996; 87(8): 3151-3160.
19. Sharfe N, Dadi HK, O'Shea JJ, Roifman CM. Jak3 activation in human lymphocyte precursor cells. Clin Exp Immunol 1997; 108: 552-556.
20. Tortolani PJ, Lal BK, Riva A, Johnston JA, Chen YQ, Reaman GH, et al. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J Immunol 1995; 155: 5220-5226.
21. Meydan N, Grunbereger T, Dadi H, Shahar M, Arpaia, E, Lapidot Z, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 379: 645-648.
22. Russell SM, Johnston JA, Noguchi M, Kawamura M, Bacon CM, Friedmann M, et al. Interaction of IL-2R beta and gama c chains with Jak1 an Jak3: implications for XSCID and XCID. Science 1994; 266: 1042-1045.
23. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993; 73: 147-157.
24. Leonard WJ. The molecular basis of X-linked severe combined immunodeficiency: defective cytokine receptor signaling. Annu Rev Med 1996; 47: 229-239.
25. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377: 65-68.
26. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995; 270: 797-800.
27. Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, et al. Human severe combined immunodeficiency: genetic phenotypic and functional diversity in one hundred eight infants. J Pediatr 1997; 130: 378-387.
28. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, et al. Defective lymphoid development in mice lacking Jak3. Science 1995; 270: 800-802.
29. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N, et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995; 3: 771-782.
30. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995; 270: 794-797.
31. Cao X, Shores EW, Hu LI J, Anver MR, Kelsall BL, Rusell SM, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995; 2: 223-238.
32. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci USA 1995; 92: 377-381.
33. Habib T, Senadheera S, Weinberg K, Kaushansky K. The common gamma chain (gamma c) is required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 2002; 41: 8725-8731.
34. Thomis DC, Aramburu J, Berg LJ. The JAK family tyrosine kinase JAK3 is required for IL-2 synthesis by naive/resting CD4+ T-cells. J Immunol 1999; 163: 5411-5417.
35. Tomita K, Saijo K, Yamasaki S, Lida T, Nakatsu F, Arase H, et al. Cytokine-independent Jak3 activation upon T cell receptor (TCR) stimulation through direct association of Jak3 and the TCR complex. J Biol Chem 2001; 276: 25378-25385.
36. Cetkovic-Cvrlje M, Dragt AL, Uckun FM. Prevention of islet allograft rejection in diabetic mice by targeting Janus kinase 3 with [4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline] (JANEX-1). Drug Research 2003; 53: 648-654.
37. Cetkovic-Cvrlje M, Roers BA, Schonhoff D, Waurzyniak B, Liu XP, Uckun FM. Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor. Leukemia and lymphoma 2002; 43: 1447-1553.
38. Cetkovic-Cvrlje M, Uckun FM. Targeting Janus kinase 3 (JAK3) in the treatment of leukemia and inflammatory diseases. AITE 2003; in press.
39. Sudbeck EA, Liu X-P, Narla RK, Mahajan S, Ghosh S, Mao C, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing anti-leukemic agents. Clin Cancer Res 1999; 5: 1569-1582.
40. Yamashita N, Kazuo S, Kitamura M, Wakao H, Furihata K, Furihata K, et al. Cyovaricin B, a new inhibitor of JAK-STAT signal transduction produced by stroptomyces torulosus. J Antibiot 1997; 50: 440-442.
41. Wasik M, Nowak I, Zhang Q, Shaw L. Suppresion of proliferation and phosphorylation of Jak3 and STAT5 in malignant T-cell lymphoma cells by derivatives of octylamino-undecyl-dimethylxanthine. Leuk Lymphoma 1998; 28: 551-560.
42. Manna S, Aggarwal B. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999; 162: 2095-2102.
43. Mattar T, Kochhar K, Bartlett R, Bremer E, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993; 334: 161-164.
44. Ghosh S, Zheng Y, Jun X, Narla R, Mahajan S, Navara C, et al. α-Cyano-β-hydroxy-β-methyl-N-[4-(trifluoromethoxy phenyl]propenamide: an inhibitor of the EGF receptor tryosine kinase with potent cytotoxic activity against breast cancer cells. Clin Can Res 1998; 4: 2657-2668.
45. Siemasko K, Chong A, Jack H, Gong H, Williams J, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998, 160: 1581-1588.
46. Fiorucci G, Percario Z, Marcolin C, Coccia E, Affabris E, Romeo G. Inhibition of protein phosphorylation modulates expression of the Jak family protein tyrosine kinases. J Virol 1995; 69: 5833-5837.
47. Nakano H, Kobayashi E, Takahashi I, Tamaoki T, Kuzuu Y, Iba H. Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. J Antibiot 1987; 40: 706-708.
48. Meggio F, Donella D, Ruzzene M, Brunati A, Cesaro L, Guerra B, et al. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem 1995; 234: 317-322.
49. Lamers M, Antson A, Hubbard R, Scott R, Williams D. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J Mol Biol 1999; 285: 713-725.
50. Caravatti G, Meyer T, Fredenhagen A, Trinks U, Mett H, Fabbro D. Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C. Bioorg Med Chem Lett 1994; 4: 399-404.
51. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, et al. Photochemical prepartion of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 2002; 12: 1219-23.
52. Wang L, Kirken R, Erwin R, Yu C, Farrar W. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tryphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol 1999; 162(7): 3897-3904.
53. Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, Wang L, et al. Tyrphostin AG-490 inhibits cytokine-mediatd JAK3/STAT5a/b signal transduction and cellula proliferation of antigen-activated human T-cells. J Leukoc Biol 1999; 65: 891-899.
54. Kirken RA, Erwin-Cohen R, Behbod F, Wang M, Stepkowski SM, Kahan BD. Tyrphostin AG-490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts. Transplant Proc 2001; 33:95.
55. Uckun FM, Ek O, Liu X-P, Chen C-L. In vivo toxicity and pharmacokinetic features of the Janus kinase 3 inhibitor WHI-P131 [4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline]. Clin. Cancer. Res. 1999; 5: 2954-2962.
56. Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002; 15: 680-9.
57. Narla RK, Liu XP, Klis D, Uckun FM. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3′-bromo-4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). Clin Cancer Res 1998; 4(10): 2463-71.
58. Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999; 5(6): 1569-82.
59. Cetkovic-Cvrlje M, Roers BA, Waurzyniak B, Liu XP, Uckun FM. Targeting Janus Kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 2001; 98: 1607-13.
60. Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, et al. Tyrosine phosphorylation and activation of STAT5, STAT3 and Janus kinases by interleukin 2 and 15. Proc Natl Acad Sci USA 1995; 92: 5705-5709.
61. Moriggl R, Sexl V, Piekorz R, Topham D, Ihle JN. Stat5 activation is uniquely associated with cytokine signaling inperipheral T-cells. Immunity 1999; 11: 225-30.
62. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999; 10: 249-259.
63. Cetkovic-Cvrlje M, Dragt AL, Vassilev A, Liu XP, Uckun FM. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabtes in NOD mice. Clin Immunol 2003; 106: 213-25.
64. Behbod F, Erwin-Cohen RA, Wang ME, Trawick BW, Qu X, Verani R, et al. Concomitant inhibition of Janus Kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat allografts. J Immunol 2001; 166: 3724-3732.
65. Saemann MD, Bohmig GA, Osterreicher CH, Staffler G, Diakos C, Krieger PM, et al. Suppression of primary T-cell responses and induction nf alloantiogen-specific hyporesponsiveness in vitro by the Janus kinase inhibitor tyrphostin AG490. Transplantation 2000; 70(8): 1215-25.
66. Mortellaro A, Songia S, Gnochi P, Ferrari M, Fornasiero C, D'Alessio R, et al. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kB and AP-1 activation. J Immunol 1999; 162: 7102-09.
67. Stepkowski SM, Nagy ZS, Wang ME, Behbod F, Erwin-Cohen R, Kahan BD, et al. PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection. Transplant Proc 2001; 33(7-8): 3272-3.
68. Saemann MD, Zeyda M, Diakos C, Szekeres A, Bohmig GA, Kelemen P, et al. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 2003; 75: 1864-1872.
69. O'Reilly RJ, Papadopoulos EB. Allogeneic Transplantation. 4th ed. Baltimore: William and Wilkins; 1997.
70. Henslee-Downey PJ. Mismatched bone marrow transplantation. Curr Opin Oncol 1995; 7(2): 115-121.
71. Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR, et al. Graft-versus-host disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone. Bone Marrow Transplant 1995; 15: 401-405.
72. O'Reilly RJ. Allogeneic bone marrow transplantation: current status and future directions. Blood 1983; 62: 941-964.
73. Butturini A, Gale RP. Allogeneic bone marrow transplantation for leukemia. Cur Opin Hematol 1994; 1: 402-405.
74. Ramsay NK, Kersey JH. Indications for marrow transplantation in acute lymphoblastic leukemia. Blood 1990; 75: 815-818.
75. Van Lochem E, De Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992; 10: 181-183.
76. Faber LM, Van Luxemburg-Heijs SA, Veenhof WF, Willemze R, Falkenburg JH. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995: 2821-2828.
77. Datta AR, Barrett AJ, Jiang JZ, Guimaraes A, Mavroudis DA, van Rhee F, et al. Distinct T-cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994; 14: 517-524.
78. Aizawa S, Kamisaku H, Sado T. An MHC-compatible allogeneic bone marrow donor with a distinct role of T-cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease. Bone Marrow Transplant 1995; 16: 603-609.
79. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant 1991; 8: 51-58.
80. Korngold R, Leighton C, Manser T. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 1994; 56: 278-287.
81. Johnson BD, Truitt RL. A decrease in graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. Transplantation 1992; 54: 104-112.
82. Salam A, Waer M. Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation. Transplantation 1996; 61: 826-830.
83. Vourka-Karussis U, Karrusis D, Ackerstein A, Slavin S. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/mice. Exp Hematol 1995; 23: 196-201.
84. Sykes M, Harty MW, Szot GL, Pearson DA. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83: 2560-2569.
85. Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999; 93: 2738-2747.
86. 2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J Immunol 1995; 154: 5542-5554.
87. Martin PJ, Hansen JA, Torok-Storb B, Durnam D, Przepiorka D, O'Quigley J, et al. Graft failure in patients receiving T-cell depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988; 3: 445-456.
88. Marmont AM, Horowitz M, Gale R, Sobocinski K, Ash R, van Bekkum D, et al. T cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
89. Poynton C. T cell depletion in bone marrow transplantation. Bone Marrow Transplant 1988; 3: 265-279.
90. Berenson RJ, Shpall EJ, Auditore-Hargreaves K, Heimfeld S, Jacobs C, Krieger MS. Transplantation of CD34+ hematopoietic progenitor cells. Cancer Invest 1996; 14(6): 589-596.
91. Apperly JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant 1986; 1: 53-60.
92. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96: 2391-2398.
93. Storb R, Pepe M, Anasetti C. What role for prednisone in prevention of graft-versus-host disease in patients undergoing marrow transplants. Blood 1990; 76: 1037-1045.
94. Atkinson K, Biggs J, Concannon A, Dodds A, Young S, Wilson F, et al. A prospective randomized trial of cyclosporine and methotrexate versus cyclosporine, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for hematological malignancy. Aust NAJ Med 1991; 21: 850-856.
95. Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR, et al. Cyclosporine and cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective randomized trials. Blood 1997; 89: 3880-3887.
96. Matherly LH, Taub JW. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leuk Lymphoma 1996; 21: 359-368.
97. Uckun FM, Roers BA, Waurzyniak B, Cetkovic-Cvrlje M. Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model. Blood 2002; 99: 4192-99.
98. Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related strains. In: Dixon FJ, editor. Adv. Immunol. N.Y.: Academic Press; 1992; p. 285-322.
99. Bowman MA, Leiter EH, Atkinson MA. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today 1994; 15: 115-120.
100. Thomas HE, Kay TWH. Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Diabetes Metabolism Res Rev 2000.
101. Wong SF, Janeway CA. The role of CD4 vs. CD8 T cells in IDDM. J Autoiimunity 1999; 13: 290-295.
102. Yoshida K, Kikutani H. Genetic and immunological basis of autoimmune diabetes in the NOD mouse. Rev Immunogenet 2000; 2: 140-146.
103. Leiter EH, Atkinson M. NOD mice an related strains: Research applications in diabetes, AIDS, cancer and other diseases. Austin, Texas, USA: R.G. Landes Company; 1997.
104. Mori Y, Suko M, Okudaira H, Matsuba I, Tsuruoka A, Sasaki A, et al. Preventive effects of cyclosporine on diabetes in NOD mice. Diabetologia 1986; 29: 244-247.
105. Miyagawa J, Yamamoto K, Hanatusa T, et al. Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. Diabetologia 1990; 33: 503-505.
106. Nicoletti F, Zaccone P, Dimarco R, Magro G, Grasso S, Morrone S, et al. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology 1995; 85(4): 645-650.
107. Gross DJ, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by linomide, a novel immunomodulating drug. Diabetologia 1994; 37(12): 1195-1201.
108. Kino K, Misumoto K, Sone T, et al. An immunomodulating protein Ling Zhi-8 (LZ-8) prevents insulitiis in non-obese diabetic mice. Diabetologia 1990; 33: 713-718.
109. Calafiore R, Basta G, Falorni A, Ietropaolo M, Picchio ML, Calcinaro F, et al. Preventive effects of azathioprine (AZA) on the onset of diabetes mellitus in NOD mice. J Endocrinol Invest 1993; 16(11): 869-873.
110. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992; 89: 174-178.
111. Kurasawa K, Koike T, Matsumura R, et al. The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. Clin Immunol Immunopathol 1990; 57: 274-279.
112. Strandell E, Sandler S. Protection against hyperglycemia in female nonobese diabetic mice treated with 15-deoxyspergualin. Autoimmunity 1992; 14: 159-165.
113. Kai N, Motojima K, Tsunoda T, Kanematsu T. Prevention of insulitis and diabetes in in NOD mice by administration of FK506. Transplantation 1993; 55: 936-940.
114. Mahon JL, Dupre J, Stiller CR. Lessons learned from the use of cyclosporine for insulin-dependent diabetes mellitus. Annals NY Acad Sci 1993; 696: 351-363.
115. Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy 1991; 11: 119S-125S.
116. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998; 14: 129-151.
117. Tian J, Olcott AP, Hanssen LR, Zekzer D, Middleton B, Kaufman DL. Infectious Th1 and Th2 autoimmunity in diabetes-prone mice. Immunol Rev 1998; 164: 119-127.
118. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4(+) T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16(1): 34-38.
119. Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 2001; 19: 131-161.
120. Formby B, Miller N, Garret R, Peterson CM. Effects of low-dose cyclosporine prophylaxis in NOD mice. J Pharm Exp Ther 1987; 241: 1106-1111.
121. Philips JM, Parish NM, Drage M, Cooke A. Cutting edge: interactions through the IL-10 receptor regulate autoimmune diabetes. J Immunol 2001; 167: 6087-91.
122. Yang Z, Chen M, Wu R, Fialkow LB, Bromberg JS, McDuffie M, et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 2002; 168: 6479-85.
123. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T-cells. J Exp Med 1996; 184: 1-8.
124. Pennline KJ, Roquegaffney E, Monahan M. Recombinant human IL-1O prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71(2): 169-175.
125. Zheng XX, Steele AW, Hancock WW, Steven AC, Nickerson PW, Roy-Chaudhury P, et al. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 1997; 158: 4507-13.
126. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976; 193: 415-417.
127. Like AA, Appel MC, Williams RM, Rossini AA, Streptozotocin-induced insulitis in mice. Lab. Invest. 1978; 38: 470-486.
128. Rakieten N. Studies on the diabetogenic action of streptozotocin. Canc Chemother Rep 1963; 29: 91-98.
129. Rossini AA, Appel MC, Williams RM, Like AA. Genetic influence of the streptozotocin-induced insulitis and hyperglycemia. Diabetes 1977; 29: 916-920.
130. Elliott JI, Dewchand H, Altmann DM. Streptozotocin-induced diabetes in mice lacking αβ T cells. Clin Exp Immunol 1997; 109: 116-120.
131. Kolb H, Kroncke K-D. IDDM. Lessons from the low-dose streptozotocin model in mice. Diabetes Review 1993; 1: 116-126.
132. Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner AG, R.E., Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992; 41: 385-391.
133. Herold KC, Montag AG, Fitch FW. Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozotocin. Diabetes 1987; 36: 796-801.
134. Bonnevie-Nielsen V, Lernmark A. An H-2 allo-antiserum preserves beta-cell function in mice made diabetic by low-dose streptozotocin. Diabetes 1986; 35: 570-3.
135. Hall BM. Cells mediating allograft rejection. Transplantation 1991; 51: 1141-51.
136. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76: 263-274.
137. Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol 2000; 12: 242-249.
138. Yun S, Sawyer GJ, Zhang X, Gustafsson K, Fabre JW. The role of IL-2 in allograft rejection - A lesson learned from experimental work. Transplantation 2000; 69: 2480-2483.
139. Mueller R, Davis JD, Krahl T, Sarvetnick N. IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection. J Immunol 1997; 159: 1599-603.
140. Li XC, Roy-Chaudhury P, Hancock WW, Manfro R, Zand MS, Li Y, et al. IL-2 and IL-4 double knockout mice reject islet allografts: A role for novel T cell growth factors in allograft rejection. J Immunol 1998; 161: 890-896.
141. Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Ohbo K, et al. The interleukin-2 receptor gamma-chain: its role in multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol 1996; 14: 179-205.
142. Steiger J, Nickerson PW, Steurer M, Moscovitch-Lopatin M, Strom TB. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 1995; 155: 489-498.
143. Schorlc HT, Holyschke T, Hunig T, Schimpl A, Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targting. Nature 1991; 252: 621-624.
144. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995; 3: 521-530.
145. Suzuki HT, Kundig M, Furlonger C, Wakeham A, Timms E, Matsuyama T, et al. Deregulated T cell activation an autoimmunity in mice lacking interleukin-2 receptor β. Science 1995; 268: 1472-1476.
146. Theze J, Alzari PM, Bertoglio J. Interleukin-2 and its receptors: recent advances and new immunological functions. Immunol Today 1996; 17: 481-486.
147. Li XC, Ima A, Li Y, Zheng XX, Malek TR, Strom TB. Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival. J Immunol 2000; 164: 1193-1199.
148. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100.
149. Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl 2001; 7: 937-42.
150. Sutherland DE, Gruessner RWG, Gruessner AC. Pancreas transplantation for treatment of diabetes mellitus. World J Surg 2001; 25: 487-496.
151. Boker A, Rothenberg L, Hernandez C, Kenyon NS, Ricordi C, Alejandro R. Human islet transplantation: update. World J Surg 2001; 25: 481-486.
152. Bretzel RG, Brendel M, Eckhard M, Brandhorst D, Jaeger C, Hatziagelaki E, et al. Islet transplantation: present clinical situation and future aspects. Exp Clin Endocrinol Diabetes 2001; 109 S2: S384-S399.
153. Shapiro JAM, Ryan EA, Lakey JRT. Pancreatic islet transplantation in the treatment of diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2001; 15: 241-264.
154. Shapiro AM, Lakey JRT, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with Type I deabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
155. Jindal RM. Posttransplant diabetes mellitus - a review. Transplantation 1994, 58: 1289-.
156. Jindal RM, Dubernard J-M. Towards a specific immunosuppression for pancreas and islet grafts. Clin Transplant 2000; 14: 242-245.
157. Zeng Y, Ricordi C, Lendoire J, Carroll PB, Alejandro R, Bereiter DR, et al. The effect of prednisone on pancreatic islet autografts in dogs. Surgery 1993; 113: 98-102.
158. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68: 396-402.
159. Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P, Steiner DE. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation 1993; 55: 186-192.
160. Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328(4): 257-65.
161. de Vries JE. Atopic allergy and other hypersensitivities. Curr Opin Immunol 1994; 6(6): 835-7.
162. Young P. Asthma and Allergies: An Optimistic Fututre.: US Department of Heatlth and Human Services; 1980.
163. Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328(4): 257-65.
164. Ishizaka K, Ishizaka T. IgE and reaginic hypersensitivity. Ann N Y Acad Sci 1971; 190: 443-56.
165. Malaviya R, Jakschik BA. Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation. J Biol Chem 1993; 268(7): 4939-44.
166. Wasserman SI. Mast cell biology. J Allergy Clin Immunol 1990; 86(4 Pt 2): 590-3.
167. Jakschik BA, Sun FF, Lee L, Steinhoff MM. Calcium stimulation of a novel lipoxygenase. Biochem Biophys Res Commun 1980; 95(1): 103-10.
168. An S, Goetzl EJ. Allergy, Principles and Practice. St. Louis, MO: Mosby-Year Book; 1998.
169. Spada CS, Nieves AL, Krauss AH, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol 1994; 55(2): 183-91.
170. Zhang Y, Ramos BF, Jakschik BA. Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 1992; 258(5090): 1957-9.
171. Henderson WR Jr, Lewis DB, Albert RK, Zhang Y, Lamm WJ, Chiang GK, et al. The importance of leukotrienes in airway inflammation in a mouse model of asthma. J Exp Med 1996: 184(4): 1483-94.
172. Spada CS, Krauss AH, Nieves AL, Woodward DF. Effects of leukotrienes B4 (LTB4) and D4 (LTD4) on motility of isolated normodense human eosinophils and neutrophils. Adv Exp Med Biol 1997: 699-706.
173. Takeda K, Hamelmann E, Joetham A, Shultz LD, Larsen GL, Irvin CG, et al. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997; 186(3): 449-54.
174. Arm JP, Lee TH. The pathobiology of bronchial asthma. Adv Immunol 1992; 51: 323-82.
175. Dahlen SE, Hansson G, Hedqvist P, Bjorck T, Granstrom E, Dahlen B. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci USA 1983; 80(6): 1712-6.
176. Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, Marfat A, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 1980; 77(7): 4354-8.
177. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340(3): 197-206.
178. Sorkness CA. The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Pharmacotherapy 1997; 17(1 Pt 2): 50S-54S.
179. Ramos BF, Zhang Y, Angkachatchai V, Jakschik BA. Mast cell mediators regulate vascular permeability changes in Arthus reaction. J Pharmacol Exp Ther 1992; 262(2): 559-65.
180. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341(8851): 989-90.
181. Brock TG, McNish RW, Peters-Golden M. Capacity for repeatable leukotriene generation after transient stimulation of mast cells and macrophages. Biochem J 1998; 329(Pt 3): 519-25.
182. Wong A, Cook MN, Hwang SM, Sarau HM, Foley JJ, Crooke ST. Stimulation of leukotriene production and membrane translocation of 5- lipoxygenase by cross-linking of the IgE receptors in RBL-2H3 cells. Biochemistry 1992; 31(16): 4046-53.
183. Abramovitz M, Wong E, Cox ME, Richardson CD, Li C, Vickers PJ. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 1993; 215(1): 105-11.
184. Gorenne I, Labat C, Gascard JP, Norel X, Muller-Peddinghaus R, Mohrs KH, et al. (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther 1994; 268(2): 868-72.
185. Smith LJ. Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents. Arch Intern Med 1996; 156(19): 2181-9.
186. Danzig M, Cuss F. Inhibition of interleukin-5 with a monoclonal antibody attenuates allergic inflammation. Allergy 1997; 52: 787-794.
187. Malaviya R, Uckun FM. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem 1999; 274: 27028-38.
188. Malaviya R, Uckun F. Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated Type 1 hypersensitivity reactions. Biochem Biophys Res Commun 1999; 257: 807-813.
189. Malaviya R, Chen CL, Navara C, Liu XP, Keenan M, Waurzyniak B, et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′, 5′-dibromo-4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). The Journal of Pharmacology and Experimental Therapeutics 2000; 295(3): 912-26.
190. Malaviya R, Chen CL, Navara C, Liu XP, Keenan M, Waurzyniak B, et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3′, 5′-dibromo-4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther 2000; 295(3): 912-26.
191. Malaviya R, Chen CL, Navara C, Malaviya R, Liu XP, Keenan M, et al. Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3″,5″-dibromo-4″-hydroxyphenyl) amino-6,7-dimethoxyquinazoline (WHI-P97). J Pharmacol Exp Ther 2000; 295: 912-26.
192. Malaviya R, Zhu D, Dibirdik I, Uckun FM. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J Biol Chem 1999; 274(38): 27028-38.
193. Malaviya R, Gao Z, Thankavel K, van der Merwe PA, Abraham SN. The mast cell tumor necrosis factor alpha response to FimH-expressing Escherichia coli is mediated by the glycosylphos-phatidylinositol- anchored molecule CD48. Proc Natl Acad Sci USA 1999; 96(14): 8110-5.
194. Globecan. Cancer Incidence, Mortality and Prevalence Worldwide. In: IARC Cancer Base No5, Lyon, IARC Press; 2001.
195. Uckun FM, Zheng Y, Cetkovic-Cvrlje M, Vassilev A, Lisowski E, Waurzyniak B, et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res 2002; 8(5): 1224-33.
196. Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson RJ, Nachman JB, et al. Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18(22): 3837-44.
197. Mitchell LG. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Cancer 2003; 97(2): 508-16.
198. Karthaus M, Doellmann T, Klimasch T, Krauter J, Heil G, Ganser A. Central venous catheter infections in patients with acute leukemia. Chemotherapy 2002; 48(3): 154-7.
199. Otten TR, Stein PD, Patel KC, Mustafa S, Silbergleit A. Thromboembolic disease involving the superior vena cava and brachiocephalic veins. Chest 2003; 123(3): 809-12.
200. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt) 2003; 17(1): 126-35, 139; discussion 139-44.
201. Uckun FM. Treating Chronic Leukemias. Minnesota Physician 2002 Decenber: 14-15.
202. Tibbles HE, Vassilev A, Wendorf H, Schonhoff D, Zhu D, Lorenz D, et al. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation. J Biol Chem 2001; 276(21): 17815-22.
203. Miyakawa Y, Oda A, Druker BJ, Kato T, Miyazaki H, Handa M, et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood 1995; 86(1): 23-7.
204. Tibbles HE, Navara CS, Hupke MA, Vassilev AO, Uckun FM. Thrombopoietin induces p-selectin expression on platelets and subsequent platelet/leukocyte interactions. Biochem Biophys Res Commun 2002; 292(4): 987-91.
205. Liu RY, Fan C, Garcia R, Jove R, Zuckerman KS. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood 1999; 93(7): 2369-79.
206. Schindler C, Strehlow I. Cytokines and STAT signaling. Adv Pharmacol 2000; 47: 113-74.
207. Miyakawa Y, Oda A, Druker BJ, Ozaki K, Handa M, Ohashi H, et al. Thrombopoietin and thrombin induce tyrosine phosphorylation of Vav in human blood platelets. Blood 1997; 89(8): 2789-98.
208. Schulze H, Ballmaier M, Welte K, Germeshausen M. Thrombopoietin induces the generation of distinct Stat1, Stat3, Stat5a and Stat5b homo- and heterodimeric complexes with different kinetics in human platelets. Exp Hematol 2000; 28(3): 294-304.
209. Witthuhn BA, Williams MD, Kerawalla H, Uckun FM. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery. Leuk. Lymphoma 1999; 32: 289-297.
210. Carri, Mt, Ferri A, Cozzolino M, Calabrese L, Rotilio G. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull 2003; 61(4): 365-374.
211. Trieu VN, Liu R, Liu XP, Uckun FM. A specific inhibitor of Janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2000; 267(1): 22-5.
212. Dibirdik I, Bofenkamp M, Skeben P, Uckun F. Stimulation of Bruton's tyrosine kinase (BTK) and mositol 1,4,5-trisphosphate production in leukemia and lymphoma cells exposed to low energy electromagnetic fields. Leuk Lymphoma 2000; 40(1-2): 149-56.
213. Ghosh S, Uckun FM. Alpha-cyano-N-(2,5-dibromophenyl)-beta-hydroxybut-2-enamide. Acta Crystallogr C 1999; 55 (Pt 8): 1364-5.
214. Ghosh S, Jennissen JD, Zheng Y, Uckun FM. Three leflunomide metabolite analogs. Acta Crystallogr C 2000; 56 (Pt 10): 1254-7.
215. Goodman PA, Niehoff LB, Uckun FM. Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells. J Biol Chem 1998; 273(28): 17742-8.
216. Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett 2002; 527(1-3): 274-8.
217. Kristupaitis D, Dibirdik I, Vassilev A, Mahajan S, Kurosaki T, Chu A, et al. Electromagnetic field-induced stimulation of Bruton's tyrosine kinase. J Biol Chem 1998; 273(20): 12397-401.
218. Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamidel. J Biol Chem 1999; 274(14): 9587-99.
219. Mahajan S, Vassilev A, Sun N, Ozer Z, Mao C, Uckun FM. Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J Biol Chem 2001; 276(33): 31216-28.
220. Malaviya R, Vassilev A, Uckun FM. 2,4,6-Trihydroxy-alpha-p-methoxyphenylacetophenone (Compound D-58) is a potent inhibitor of allergic reactions. Am J Ther 2001; 8(6): 417-24.
221. Mao C, Zhou M, Uckun FM. Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem 2001; 276(44): 41435-43.
222. Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999; 5(6): 1569-82.
223. Tibbles H, Vassilev A, Uckun FM. A dual function anti-leukemic agent with anti-thrombotic activity. Leuk Lymphoma 2002; 43(5): 1121-7.
224. Uckun FM, Waddick KG, Mahajan S, Jun X, Takata M, Bolen J, et al. BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Science 1996; 273(5278): 1096-100.
225. Uckun FM. Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem Pharmacol 1998; 56(6): 683-91.
226. Uckun FM, Sudbeck EA, Mao C, Ghosh S, Liu XP, Vassilev AO, et al. Structure-based design of novel anticancer agents. Curr Cancer Drug Targets 2001; 1(1): 59-71.
227. Uckun FM. Rationally designed anti-mitotic agents with proapoptotic activity. Curr Pharm Des 2001; 7(16): 1627-39.
228. Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem 1999; 274(3): 1646-56.
229. Zhu DM, Narla RK, Fang WH, Chia NC, Uckun FM. Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. Clin Cancer Res 1998; 4(12): 2967-76.
230. Zhu DM, Uckun FM. Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. Clin Cancer Res 2000; 6(6): 2456-63.
231. Zhu DM, Tibbles HE, Vassilev AO, Uckun FM. SYK and LYN mediate B-cell receptor-independent calcium-induced apoptosis in DT-40 lymphoma B-cells. Leuk Lymphoma 2002; 43(11): 2165-70.
232. Murata A. Granulocyte colony-stimulating factor as the expecting sword for the treatment of severe sepsis. Curr Pharm Design 2003; 9(14): 1115-20.
233. Pullerits T. Cytokine modulation for anti-allergic treatment. Curr Pharm Design 2002; 8(20): 1845-53.
234. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Design 2002; 8(25): 2255-7.